Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F16%3A10326077" target="_blank" >RIV/00064165:_____/16:10326077 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/16:10326077

Výsledek na webu

<a href="http://dx.doi.org/10.1080/14737175.2016.1181543" target="_blank" >http://dx.doi.org/10.1080/14737175.2016.1181543</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1080/14737175.2016.1181543" target="_blank" >10.1080/14737175.2016.1181543</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine

Popis výsledku v původním jazyce

Introduction: Brain atrophy measurement in multiple sclerosis (MS) has become an important outcome for determining patients at risk for developing physical and cognitive disability. Areas covered: In this article, we discuss the methodological issues related to using this MRI metric routinely, in a clinical setting. Understanding trajectories of annualized whole brain, gray and white matter, thalamic volume loss, and enlargement of ventricular space in specific MS phenotypes is becoming increasingly important. Evidence is mounting that disease-modifying treatments exert a positive effect on slowing brain atrophy progression in MS. Expert Commentary: While there is a need to translate measurement of brain atrophy to clinical routine at the individual patient level, there are still a number of challenges to be met before this can actually happen, including how to account for biological confounding factors and pseudoatrophy, standardize acquisition and analyses parameters, which can influence the accuracy of the assessments.

Název v anglickém jazyce

Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine

Popis výsledku anglicky

Introduction: Brain atrophy measurement in multiple sclerosis (MS) has become an important outcome for determining patients at risk for developing physical and cognitive disability. Areas covered: In this article, we discuss the methodological issues related to using this MRI metric routinely, in a clinical setting. Understanding trajectories of annualized whole brain, gray and white matter, thalamic volume loss, and enlargement of ventricular space in specific MS phenotypes is becoming increasingly important. Evidence is mounting that disease-modifying treatments exert a positive effect on slowing brain atrophy progression in MS. Expert Commentary: While there is a need to translate measurement of brain atrophy to clinical routine at the individual patient level, there are still a number of challenges to be met before this can actually happen, including how to account for biological confounding factors and pseudoatrophy, standardize acquisition and analyses parameters, which can influence the accuracy of the assessments.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FH - Neurologie, neurochirurgie, neurovědy

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Expert Review of Neurotherapeutics

ISSN

1473-7175

e-ISSN

—

Svazek periodika

16

Číslo periodika v rámci svazku

7

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

17

Strana od-do

777-793

Kód UT WoS článku

000379025500007

EID výsledku v databázi Scopus

2-s2.0-84976423714